Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.44 |
| ▸ | SCN1A | P35498 | 3/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.42 |
| ▸ | HRH1 | P35367 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28254705 | 0.89 | KCNA5 (0.49) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| SCHEMBL29031285 | 0.87 | KCNA5 (0.47) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| SCHEMBL28347623 | 0.86 | KCNA5 (0.46) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| SCHEMBL21405673 | 0.86 | KCNA5 (0.46) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| SCHEMBL28260638 | 0.86 | KCNA5 (0.46) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| SCHEMBL28669183 | 0.86 | KCNA5 (0.46) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| SCHEMBL29145046 | 0.86 | KCNA5 (0.46) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| Bromide SCHEMBL9168336 | 0.86 | KCNA5 (0.46) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| SCHEMBL28130837 | 0.86 | KCNA5 (0.46) | KCNA5KCNH2CYP2D6KCNE1TSHR | |
| Water SCHEMBL28366590 | 0.84 | KCNA5 (0.45) | KCNA5KCNH2CYP2D6KCNE1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2024-09-12 | — | — | US | disclosed |
| EP-3483143-B1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3483143-B1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011153509-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011153509-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| EP-1044991-B1 | Process of preparing curable compositions and compositions therefrom | ROHM & HAAS (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6645562-B2 | Drying a coating of a liquid addition oligomer having pendant functional groups; modifying by curing and crosslinking with an unsaturated compound having a reactive group using a free radical catalyst; films, adhesives, coatings, paints and inks | GREENBLATT GARY DAVID (US) | 2003-11-11 | — | — | US | disclosed |
| US-20030069363-A1 | Method of preparing a curable coating and curing thereof | GREENBLATT GARY DAVID (US) | 2003-04-10 | — | — | US | disclosed |
| US-20020137857-A1 | Forming an oligomer containing reactive functional groups,and reacting a modifier that also contains reactive function groups with the oligomer | ROHM AND HAAS COMPANY | 2002-09-26 | — | — | US | disclosed |
| US-6433098-B1 | CROSSLINKING; PHOTOPOLYMERIZATION | ROHM AND HAAS COMPANY | 2002-08-13 | — | — | US | disclosed |
| EP-1044991-A1 | Process of preparing curable compositions and compositions therefrom | ROHM AND HAAS COMPANY (US) | 2000-10-18 | — | — | EP | disclosed |
| CN-1270186-A | Method for preparing curable composition and composition therefrom | ROHM & HAAS (US) | 2000-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885CYP2D6 2390/4885 |
| US-20110319378-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885CYP2D6 2390/4885 |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | TP53, HIF1AN, MDM2 | KCNA5 3702/4885KCNH2 4455/4885CYP2D6 3100/4885 |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885CYP2D6 2390/4885 |
| US-20210179560-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | KCNA5 4353/4885KCNH2 4697/4885CYP2D6 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.